Business Wire

Mavenir Announces Virtualized Network Slicing Suite for 4G/5G

Jaa

Mavenir, focused on accelerating software network transformation and redefining network economics for Communications Service Providers, today announced its virtualized network slicing software solution called CloudRange™ Network Slice Suite that enables end-to-end network slicing for radio, core and applications, both in 4G and 5G networks.

As mobile operators are preparing their networks for 5G and IoT, the increasing and varying connectivity demands present an opportunity for new business models. Network slicing creates multiple networks that share the same physical infrastructure. This allows operators to dedicate a portion of their network to a certain functionality and makes it easier to deploy 5G applications.

Operators can use their existing network for slicing selected services and create additional slices for new, differentiated services that increase revenues. The Network Slice Suite works across radio, core, and applications to allow criteria that are required for practical deployments such as subscriber data/intelligence in the network, MVNO network setup, and network upgrade with virtualized multi-vendor deployments.

“Having the capability to apply network slicing to existing 4G networks today provides operators with a new set of options to offer new bespoke services and reduce costs of existing traffic. We have built a slicing orchestrator function that works across the radio, the core and applications,” said Pardeep Kohli, President and CEO, Mavenir. “Until now, it’s just been applications and core running through NFV but we are implementing a similar approach with Mavenir’s Cloud RAN which includes radio slicing. We are essentially redefining the mobile network economics today and providing a runway for migration to 5G.”

“Operators are looking for more complete slicing solutions that involve all parts of a service from end-to-end,” stated Michael Howard, executive director, research and analysis, carrier networks, IHS Markit. “Mavenir now offers a new approach with virtualized end-to-end operations including the radio slicing, which changes the cost equation for most operators and makes it easier for them to deploy 4G and 5G networks.”

CloudRange Network Slice Suite supports network slicing in 4G networks and 5G Ready networks, and includes Slicing Selection Function (SSF) for radio, NAS Network Selection Function (NNSF) for packet core Mobility Management Entities selection and Core Gateway Network Selection (CGNS) for packet core Control and User Plane gateway entities selection. Service Orchestration (SO) allows E2E setup of services and interfaces with SDN-C for programming the underlying network.

CloudRange, Mavenir’s network functions virtualization (NFV) and container management and orchestration (MANO) platform, is built with a Cloud Native and Web-Scale architecture, drastically driving down the network economics for mobile operators with scalability, efficiency and automation.

About Mavenir:

Mavenir is purpose-built to redefine mobile network economics for Communication Service Providers (CSPs). Our solutions pave the way to 5G with 100% software-based, end-to-end, Cloud Native network solutions. Leveraging industry-leading firsts in VoLTE, VoWiFi, Advanced Messaging (RCS), Multi-ID, vEPC and Cloud RAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 130 countries, serving over 50% of the world’s subscribers.

We embrace disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to CSPs for revenue generation, cost reduction and revenue protection. www.mavenir.com

Mavenir, the M logo, and CloudRange are trademarks owned by Mavenir Systems, Inc.

Copyright © 2017 Mavenir Systems, Inc. All Rights Reserved.

Contact information

Mavenir
Maryvonne Tubb
pr@mavenir.com
or
Loren Guertin
mavenir@matternow.com
or
Hannah Locke
mavenir@hotwirePR.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Andersen Global Expands Presence in Germany with Addition of Thierhoff Müller & Partner13.12.2017 11:01Tiedote

Andersen Global is proud to announce an expanded presence in Germany as Thierhoff Müller & Partner, a tax and legal firm with offices in Leipzig and Frankfurt, combines its practice with Andersen Tax & Legal in Germany. Through its German member firms, Andersen Tax & Legal and Alegis Steuerberatungsgesellschaft mbH, Andersen Global now has more than 65 professionals focused on providing tax and legal services and business advice across five locations in Germany, including Cologne, Dusseldorf, and Merzig. “Thierhoff Müller is highly regarded in complex restructuring matters. Together with our existing legal and tax practice, we will be able to increase our service offerings for our clients,” said Stefan Kraus, Managing Partner of Andersen Tax & Legal in Germany. “We are dedicated to providing outstanding service and are adding additional competencies in tax and legal such as corporate r

Aprecia Pharmaceuticals and Cycle Pharmaceuticals Partner to Develop 3D-Printed Orphan Drugs13.12.2017 11:00Tiedote

Aprecia Pharmaceuticals, LLC (“Aprecia”), The 3DP Pharmaceutical Company, and Cycle Pharmaceuticals, Ltd. (“Cycle”) today announced they have signed a partnership agreement to develop and commercialize orphan drugs using three-dimensionally printed (“3DP”) technology. The planned products will deliver quality-of-life improvements versus existing, approved orphan drugs, and will achieve this by utilizing Aprecia’s proprietary 3DP ZipDose® Technology platform. ZipDose® is the only three-dimensional printing technology used in a pharmaceutical drug product approved by the U.S. Food and Drug Administration. Antonio Benedetti, CEO of Cycle commented: “Many rare disease patients do not have a treatment option at all. For those rare diseases where there is an approved pharmaceutical treatment, patients continue to be burdened by sub-optimal drug formulations. Aprecia’s

Group Vivendi Africa Deploys Netcracker OSS to Enhance Service Management as it Expands Across the Continent12.12.2017 19:07Tiedote

Netcracker Technology announced today that its OSS suite was selected and deployed to support the long-term growth strategy of Group Vivendi Africa (GVA). GVA is a newly formed affiliate of the French-based multinational conglomerate Vivendi with the goal to deploy and operate a fiber network across Africa. Netcracker's OSS will be used as a consolidated solution to identify service availability across GVA's operating countries and then fulfill and provision those services to customers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005937/en/ Netcracker's highly productized, out-of-the-box applications enabled the OSS suite to be deployed in seven months, meeting GVA's demand to leverage an integrated service fulfillment and inventory solution that could satisfy its long-term growth expectations, as well as s

Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program12.12.2017 18:23Tiedote

Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today released its latest Scientific Update for Smoke-Free Products, a regular publication on its research efforts to develop and assess a range of smoke-free alternatives to cigarettes. The latest issue of the Scientific Update can be found at this link. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005891/en/ Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program (Photo: Business Wire) This issue of the Scientific Update provides a closer look at some of the principles and practices on which PMI’s scientific assessment program is built. Director Medical Affairs Dr. Patrick Picavet describes specific examples from PMI’s clinical program that highlight the company’s

Murex to Offer MX.3 Risk, Trading and Post-Trade Solutions on the AWS Cloud12.12.2017 17:00Tiedote

Murex, an industry leader in trading, risk management and processing solutions for capital markets, announced they will run their MX.3 technology platform on Amazon Web Services, Inc. (AWS). With the acceleration of cloud adoption in capital markets, Murex and AWS agreed to collaborate to help clients migrate their Murex application workloads to the AWS Cloud. Murex clients are looking to consolidate more and more of their capital markets activity on the MX.3 platform and this means their need for infrastructure is increasing. New regulatory requirements are also driving financial organizations to use cloud to scale up their computing capacity. Murex is collaborating with AWS to meet the demand from clients to support deployment of the Murex offering on the AWS Cloud. Murex is working on the validation of a range of deployment scenarios, from using AWS Cloud for bursting grid

Darzalex®▼(daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible12.12.2017 16:33Tiedote

Janssen-Cilag International NV (“Janssen”) today announced data from the Phase 3 ALCYONE study, showing Darzalex® (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT).1 These data were accepted as a late-breaking abstract (LBA) for presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, today at 7:30 a.m. ET (Abstract #LBA-4).1 Study findings were simultaneously published in the New England Journal of Medicine (NEJM) . 2 Daratumumab is currently indicated for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme